BTP1000 & The Clearance of Mucus From the Lungs

BTP1000

• 批准号: 6550173
• 负责人: Donovan B Yeates
• 金额: $ 13.59万
• 依托单位: BIOTECHPLEX CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-15 至 2003-10-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6550173
• 关键词: asthma; bronchiectasis; chronic bronchitis; chronic obstructive pulmonary disease; cystic fibrosis; drug design /synthesis /production; epithelium; expectorant /mucolytic; mucus; respiratory airway clearance; respiratory pharmacology; sheep; viscosity

DESCRIPTION (provided by applicant): Patients with chronic bronchitis, bronchiectasis, cystic fibrosis, asthmatic bronchitis and asthma have inspissated mucus and plugs of highly viscoelastic mucus. The inability to clear this mucus leads to impaired airway function and gas exchange and consequent morbidity and mortality. Present pharmacological therapies to treat such abnormalities, although widely applied in clinical practice, are inadequate and many have little or no scientific basis. BioTechPlex proposes to demonstrate the mechanisms of action and efficacy of a new therapeutic regime (BTP1000) to hydrate the airways and enhance mucociliary clearance. The specific aim of this Phase I project is to provide the preliminary data to support the novel intracellular mechanisms underlying the rationale for the use of BTP 1000 to increase airway hydration and ciliary beat frequency; factors that can be predicted to increase the clearance of secretions from the lungs. BioTechPlex will utilize its in-depth expertise in the mechanisms governing ion and water transport across epithelium and ciliary activity as well as its advanced technologies for the investigation of these airway epithelial functions. In the Phase II project the mechanisms of action of BTP1000 will be further expanded, validated and shown to substantially increase bronchial mucociliary clearance in dogs with minimal side effects.

描述（由申请人提供）：慢性支气管炎、支气管扩张、囊性纤维化、哮喘性支气管炎和哮喘患者有浓稠的粘液和高粘弹性粘液塞。无法清除这种粘液会导致气道功能和气体交换受损，从而导致发病率和死亡率。目前治疗此类异常的药物疗法虽然在临床实践中得到了广泛应用，但仍存在不足，许多疗法几乎没有科学依据。BioTechPlex计划展示一种新的治疗方案（BTP1000）的作用机制和疗效，以水化气道并增强粘膜纤毛清除。这个第一阶段项目的具体目的是提供初步数据，以支持使用BTP 1000增加气道水化和纤毛搏动频率的新细胞内机制；这些因素可以预测会增加肺部分泌物的清除率。BioTechPlex将利用其在控制离子和水在上皮和纤毛活动中的运输机制方面的深入专业知识，以及对这些气道上皮功能的研究的先进技术。在II期项目中，BTP1000的作用机制将进一步扩展、验证，并显示其能显著增加狗的支气管粘膜纤毛清除率，且副作用最小。